Module 2: General Toxicology
Recorded On: 08/05/2021
This eLearning module will focus on the principles of general toxicology. The presentation will provide an overview of the basic tenets of toxicology testing and the general assumptions made during the generation of nonclinical data. It will teach you how to develop a nonclinical safety assessment plan showing you how the safety assessment program is designed regarding general regulations and guidelines and how specific aspects of a chemical/product class can influence the design of the program. The module will also discuss study design considerations for toxicology studies and general regulatory requirements, as well as specific design parameters (route of administration, duration of treatment, selection of species, dose selection, and parameters assessed), briefly explaining large- versus small-molecule development considerations. Moreover, it will highlight the importance of the interpretation of toxicology study results, especially as it concerns to what is an adverse finding and in defining the NOAEL. Finally, the regulatory application of the nonclinical data to clinical dose selection will be covered, ensuring that a comprehensive and robust nonclinical safety assessment package can be submitted in support of new drug applications to regulatory agencies worldwide.
Lorrene A. Buckley, PhD, DABT, ATS
Vice President
Eli Lilly & Company
Dr. Lorrene Buckley is a board-certified toxicologist with over 30 years of experience in the active practice of toxicology. She earned her degrees in Toxicology, an MS from the University of Arizona, and a PhD from the University of North Carolina at Chapel Hill, in collaboration with the laboratories of the NIEHS and US EPA. She is certified by the American Board of Toxicology (ABT) and is a Fellow of the Academy of Toxicological Sciences (ATS).
Dr. Buckley’s diversity of professional experience as a toxicologist is reflected in her work spanning basic and applied toxicology research and risk assessment in the industrial chemical, agrochemical, and pharmaceutical industries. As a Vice President at Eli Lilly & Company, she was responsible for the design and execution of nonclinical safety assessment programs as well as for nonclinical aspects of global regulatory submissions and interactions for drugs in the development and commercialization phases. Dr. Buckley has authored the pharmacology/toxicology sections of numerous regulatory documents, including briefing documents, INDs/IMPDs, BLAs/NDAs, investigator brochures, annual reports, as well as safety information on product labels/package inserts.
Her contributions to the profession of toxicology include service on the Boards of the ABT and the ATS (past President) and on the Councils of the ACT (past President) and the SOT.